EP1341759B1 — 3-substituted oxindole beta 3 agonists
Assigned to Eli Lilly and Co · Expires 2006-06-14 · 20y expired
What this patent protects
The present invention relates to a beta<SUB>3 </SUB>adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
USPTO Abstract
The present invention relates to a beta<SUB>3 </SUB>adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.